Clinical Trial

In Vivo Noradrenergic System and Aging

Study acronym: NA2C-PET-MRI
Recruiting
View on ClinicalTrials.gov →
Summary
The main goal of this research proposal is to provide, for the first time in humans, a wider understanding of the role of the noradrenergic system both in health and illness (here Parkinson's disease) through the use of a newly developed radiotracer visualizing alpha2C-ARs (\[11C\]ORM-13070) combined with a cutting-edge technology, the hybrid PET/MRI scanner. The secondary aim will be to determine whether the expected age- and PD-related changes in the noradrenergic system are paralleled by changes in neuropsychological performances (i.e. cognitive, motor and/or olfactory abilities).
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-10
notable Primary completion moved earlier: 2029-10 -> 2029-09 2026-07-10
minor Completion moved earlier: 2029-10 -> 2029-09 2026-07-10
Trial Details
NCT Number NCT07569120
Lead Sponsor Hospices Civils de Lyon
Conditions Healthy Aging and Parkinson's Disease
Enrollment 165 participants
Start Date 2026-06-29
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-09